Comparative Pharmacology
Head-to-head clinical analysis: ALOPRIM versus FEBUXOSTAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALOPRIM versus FEBUXOSTAT.
ALOPRIM vs FEBUXOSTAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Allopurinol inhibits xanthine oxidase, the enzyme responsible for the conversion of hypoxanthine to xanthine and xanthine to uric acid, thereby reducing serum and urinary uric acid concentrations.
Febuxostat is a non-purine selective inhibitor of xanthine oxidase (XO). It inhibits both oxidized and reduced forms of XO, thereby reducing the conversion of hypoxanthine to xanthine and xanthine to uric acid, leading to decreased serum uric acid levels.
300 mg orally once daily; may be increased to 600-800 mg/day in divided doses for severe gout.
40 mg orally once daily; may increase to 80 mg orally once daily if serum urate goal not achieved after 2 weeks.
None Documented
None Documented
Clinical Note
moderateFebuxostat + Theophylline
"The serum concentration of the active metabolites of Theophylline can be increased when Theophylline is used in combination with Febuxostat."
Clinical Note
moderateFebuxostat + Aminophylline
"The serum concentration of the active metabolites of Aminophylline can be increased when Aminophylline is used in combination with Febuxostat."
Clinical Note
moderateFebuxostat + Dyphylline
"The serum concentration of the active metabolites of Dyphylline can be increased when Dyphylline is used in combination with Febuxostat."
Clinical Note
moderateAllopurinol: 1-2 h; Oxypurinol: 18-30 h (prolonged in renal impairment, up to 7 days in severe CKD)
Terminal elimination half-life: 5-8 hours in healthy subjects; prolonged in renal impairment (e.g., up to 9.6 hours in moderate impairment). Clinical context: dosing interval is once daily, consistent with half-life.
Renal: ~70% (30% as allopurinol, 40% as oxypurinol); fecal: ~20%; biliary: minor (<5%)
Renal: 1-3% unchanged; biliary/fecal: ~50% as metabolites (acyl glucuronides, oxidative metabolites); other: ~49% metabolized and eliminated via multiple pathways including biliary and direct intestinal excretion of unchanged drug.
Category C
Category C
Xanthine Oxidase Inhibitor
Xanthine Oxidase Inhibitor
Azathioprine + Febuxostat
"The serum concentration of Febuxostat can be increased when it is combined with Azathioprine."